Read More Pharma Industry News Pfizer’s danuglipron shows promising results in Phase 2b obesity trial Pfizer Inc. (NYSE: PFE) has announced encouraging topline data from its Phase 2b clinical trial (NCT04707313) investigating danuglipron,… byPallavi MadhirajuDecember 3, 2023